

FACT SHEET

Summary of SCIP Measure Changes for 04/01/11+ Discharges

Summary of SCIP Measure Changes

The information below consists of new changes in abstraction and changes provided for clarification only for SCIP measure changes.

SCIP VTE 1 and VTE 2:

- A change was made in the Denominator Statement – Excluded Populations to say: Patients who stay less than two nights. This change was made to be consistent with the measure exclusions wherein patients with a Length of Stay that is less than 3 calendar days are excluded.
- The references were updated.

Appendix A:

- These surgeries are extensive abdominal or rectal surgeries that often require urinary catheterization beyond 2 days therefore the codes are being excluded from Inf-9 by adding them to Table 5.16.
 - 46.03 LG BOWEL EXTERIORIZATION
 - 45.95 ANAL ANASTOMOSIS
- Most transplant procedures are already excluded from Inf-4. To maintain consistency, heart transplants are being removed from Inf-4 therefore the following code was removed from Table 5.11:
 - 37.51 HEART TRANSPLANTATION
- Antibiotics are not recommended for this procedure so it is being removed from the infection measures therefore the following code was removed from Table 5.08 and added to Table 5.25:
 - 38.18 LOWER LIMB ENDARTERECT
- Providers will no longer be able to submit 'non-covered' procedure codes that are performed in the same inpatient stay with the covered procedure(s) on inpatient claims which means these 4 codes may no longer be included as principal procedure codes and were removed from Tables 5.10, 5.11 and 5.25:
 - 37.35 PARTIAL VENTRICULECTOMY
 - 37.52 IMP TOT INT BI HT RP SYS
 - 37.53 REPL/REP THR UNT TOT HRT
 - 37.54 REPL/REP OTH TOT HRT SYS

Appendix C:

- Utira C: Methenamine was added to table 3.11.

Appendix H:

- Rivaroxaban was removed from Table 2.1 as it has not been approved by the FDA.

Data Element or Table:	<i>Anesthesia Start Time</i>
Type of Change:	Clarification <ul style="list-style-type: none">• The inclusion terms, Anesthesia start, begin and initiated were added.

Data Element or Table:	<i>Antibiotic Administration Date</i>
Type of Change:	Clarification <ul style="list-style-type: none">• Clarification was added to explain how to determine the date using surrounding documentation if the date is not documented.

Data Element or Table:	<i>Reasons to Extend Antibiotics</i>
Type of Change:	Clarification <ul style="list-style-type: none">• The Suggested Data Question was clarified to say: What reason was documented by a physician/APN/PA for extending the duration of the antibiotic administration past 24 hours (48 hours for CABG or Other Cardiac Surgery) after <i>Anesthesia End Time</i>?• The data element was revised by condensing the Allowable Values to clearly delineate which Values require correlated documentation with the use of an antibiotic and the reason that the use of the antibiotic was extended.• Value 6 was removed because it was redundant to a Value in <i>Infection Prior to Anesthesia</i>.

Data Element or Table:	<i>VTE Prophylaxis</i>
Type of Change:	Clarification <ul style="list-style-type: none">• Value 8 Oral Factor Xa Inhibitor was removed from the Allowable Values because Rivaroxaban has not been FDA approved.

For a complete list of changes please see the “Release Notes,” located in the Specifications Manual for National Hospital Quality Measures for discharges 4/1/2011. The manual can be found at:

<http://www.qualitynet.org/dcs/ContentServer?cid=1192804535739&pagename=QnetPublic%2FPage%2FQnetTier3&c=Page>

This material was prepared by Oklahoma Foundation for Medical Quality, the Medicare Quality Improvement Organization for Oklahoma, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents presented do not necessarily reflect CMS policy. 4-1180-OK-0211